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Abstract Li Fraumeni Syndrome (LFS) is a hereditary
cancer syndrome characterized by a high risk of developing
various types of cancer from birth through late adulthood.
Clinical beneﬁts of surveillance for LFS are limited. The
aim of this study is to investigate which advice for regular
surveillance, if any, is given to high risk LFS individuals,
adherence to that advice, and any psychological gain or
burden derived from surveillance. Fifty-ﬁve high risk indi-
viduals(provencarriersandthoseat50%risk)fromfamilies
with a p53 germline mutation were invited to participate, of
whom 82% completed a self-report questionnaire assessing
advice for regular surveillance, compliance, perceived
beneﬁts and barriers of screening and LFS-related distress
(IES) and worries (CWS). In total, 71% of the high risk
family members received advice to undergo regular sur-
veillance for LFS. The majority (78%) reported adherence
with the recommended advice. All high risk women aged 25
or older reported having been advised to undergo annual
breast cancer surveillance (n = 11), of whom 64% (n = 7)
in speciﬁc received advice to undergo a mammography.
Seventy-eight percent of respondents indicated having
receivedtailoredsurveillance advicebased onfamily cancer
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DOI 10.1007/s10689-010-9368-zhistory. The large majority of respondents believed in the
value of surveillance to detect tumors at an early stage
(90%) and reported that it gave them a sense of control
(84%) and security (70%). Despite its limited clinical ben-
eﬁts, the majority of high risk LFS family are advised to
undergo, and are adherent to, and report psychological
beneﬁt from, regular surveillance programs.
Keywords Li-Fraumeni syndrome (LFS)  Surveillance 
Compliance  Psychological barriers and beneﬁts
Introduction
Li Fraumeni Syndrome (LFS) is a rare, autosomal domi-
nant, inherited cancer syndrome characterized by a high
risk of developing various types of cancer from birth
through late adulthood. The only known cause of LFS is a
germline mutation in the p53 gene [1]. Carriers of a p53
germline mutation have a life-time risk of *90% of
developing a malignancy. The risk for women seems to be
higher than for men, which partly can be explained by
breast cancer occurrence [2, 3]. Approximately 20% of the
carriers develop cancer before the age of twenty [3], and
may develop multiple primary cancers [4]. The most fre-
quently occurring malignancies in LFS are pre-menopausal
breast cancer, sarcomas, leukemia and brain tumors [5].
In cancer care, in general, the main aim of periodic
surveillance (and of interventions that result from surveil-
lance) is to prevent cancer or detect expression of the
disease at the earliest possible stage in order to affect
prognosis positively. In the more common forms of
hereditary cancer, like hereditary breast and ovarian cancer
(HBOC) and Lynch syndrome, periodic surveillance and
risk reducing interventions have found to be beneﬁcial in
reducing mortality and morbidity in high risk family
members [6–8]. In the case of LFS, however, debate is
ongoing on which surveillance methods to offer and, in
particular, what the medical gains of these methods are
[5, 9, 10]. Given the wide range of tumor sites and age of
onset, it is difﬁcult to have effective periodic surveillance.
Novel surveillance imaging techniques for LFS, such as
full body MRI scan in thick slices and FDG-PET/CT scans,
are currently being investigated [11]. However, at present,
the only surveillance method that is thought to be effective
is regular surveillance for breast cancer in women aged
20–25 or older. However, due to the possible radiation
sensitivity associated with p53 mutations [12], there is
considerable discussion about which breast surveillance
method to use, mammography or breast MRI [5].
According to Varley et al., high risk individuals from
families with a p53 mutation should avoid radiation
whenever possible [13]. The diagnostic and preventive
guidelines for LFS in the Netherlands state that, apart from
regular breast cancer surveillance from the age of
20–25 years and onward, an annual anamnesis and physi-
cal examination could be considered [14].
To our knowledge, no study has investigated what type
of advice for regular surveillance has actually been given to
high risk LFS family members, or the extent to which such
advice is followed. There is also a paucity of information
on the perceived psychological barriers and beneﬁts of
regular surveillance for LFS. Given that LFS family
members consider ‘being able to plan surveillance as one
of the most important reasons for undergoing genetic
testing [15], we hypothesized that they would also expe-
rience psychological beneﬁts from undergoing regular
surveillance. Although the medical gains associated with
regular surveillance remain the subject of debate, it may
provide high risk family members with a sense of control
over the disease [16].
The speciﬁc aims of this study were: (1) to evaluate what
advice for regular surveillance is given to high risk LFS
familymembers,(2)toassess adherence tothe advice given,
(3)toevaluatetheself-reportedreasonsfor(non)compliance
with this advice; and (4)toinvestigatethe perceived barriers
and beneﬁts of regular surveillance for LFS.
Methods
Study sample and procedures
As part of a larger, cross-sectional study performed in
collaboration with all 9 family cancer clinics (FCC) in the
Netherlands and the DNA-laboratory of the Netherlands
Cancer Institute, 18 families with a p53 germline mutation
were identiﬁed. Four of these families were ineligible
because all registered adult family members were deceased
at the time of the study. In two families, no high risk family
members were identiﬁed. In total, 55 high risk family
members (carriers and those at 50% risk) from the
remaining 12 families were invited to take part in the study.
Family members were invited via their clinical geneticist.
Those who could not be invited through the FCC, such as
those at 50% risk who had not received genetic counseling,
were invited by a contact person within the family. Family
contact persons were typically key ﬁgures within the
family who assisted in drawing the family pedigree.
Excluded from this part of the study were individuals
younger than 16 years of age and those not aware that LFS
runs in their family (n = 3). Eligible family members
received an invitation letter and self-report questionnaire
by mail. In case of non-response after 2 weeks, reminders
per mail and telephone were used. Family members were
recruited between August 2006 and February 2008. The
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123study was approved by the institutional review boards of all
participating hospitals.
Measures
Sociodemographic and clinical variables
Age, gender, marital status, education, offspring, personal
history of cancer and DNA-status (carrier, 50% at-risk,
non-carrier) were obtained from the self-report question-
naire and the medical records.
Advice for, and adherence to, regular surveillance
A series of questions was posed to determine what meth-
ods, if any, for regular surveillance had been advised, and
adherence to those recommendations. Compliers were
deﬁned as those who indicated that they had adhered to
the advice given or more frequently than advised. Non-
compliers were deﬁned as those who do not undergo one or
more of the advised surveillance methods and/or less fre-
quently than had been advised. Where relevant, reasons for
non- or under compliance were asked.
Perceived beneﬁts and barriers of screening
Perceived beneﬁts and barriers of regular surveillance for
LFS were assessed with an 11-item scale adapted from
previous work carried out by Champion [17], Kash et al.
[18], and Madalinska et al. [19]. This included 5 ‘‘pro’’
statements and 6 ‘‘con’’ statements about regular surveil-
lance. An example of a pro statement is: ‘‘Regular sur-
veillance for LFS provides me with a feeling of control’’.
An example of a con statement is: ‘‘Regular surveillance
can cause unnecessary worry’’. Response categories ran-
ged on a ﬁve-point scale from ‘strongly disagree’ to
‘strongly agree’. Sum scores for the pro and con subscales
ranged from 5 to 25, and 6 to 30, respectively. Reliability
(Cronbachs’ coefﬁcient alpha) of the pro and con subscales
was .83 and .45, respectively.
LFS-speciﬁc distress
LFS-speciﬁc distress was measured with the ‘intrusion’
subscale of the Impact of Event Scale [20]. This 7-item
questionnaire measures intrusive thoughts and feelings
about LFS during the past 7 days. The IES-intrusion total
score ranges between 0–35. A score of 9 or higher is
considered to be clinically relevant [21], and additional
psychosocial help may be indicated. The Dutch version of
the IES has proven to be a valid and reliable instrument for
assessing disease-speciﬁc distress [20]. Cronbach’s alpha
for the intrusion scale was 0.91.
LFS-related worries
LFS-related worries were assessed with an 8-item ques-
tionnaire adapted from the Cancer Worry Scale (CWS)
[22, 23]. Scores range from 8 to 32, with higher scores
indicating more frequent worries about cancer. Cronbach’s
alpha in the present study was 0.89.
Statistical analysis
Descriptive statistics were used to characterize the study
sample, to describe the various recommended surveillance
methods, to assess adherence with surveillance, and to
investigate the perceived beneﬁts and barriers of surveil-
lance for LFS. Univariate analyses (analysis of variance,
Student t test, Fisher’s exact test, chi square) were used to
investigate possible differences between those who did and
did not receive an advice for regular surveillance and
between compliers and non-compliers in terms of soci-
odemographic, clinical and psychological variables.
Because data on LFS-speciﬁc distress were positively
skewed and leptokurtic, we log transformed the data in
order to meet the assumptions for parametric testing.
However, since the results using this method did not differ
signiﬁcantly from those based on parametric tests, we
report here the results of the parametric test with the
untransformed data only.
It was not possible to control for potential clustering
effects (i.e., multiple family members from the same
family) due to the fact that in four families only a single
family member participated in the study.
All analyses were conducted using the Statistical
Package for the Social Sciences (version 17.0).
Results
Response
In total, 45 (82%) high risk family members (carriers and
those at 50% risk) completed the questionnaire. No sta-
tistically signiﬁcant differences were found between the 45
respondents and the 10 non-respondents for gender or age.
The respondents stemmed from 9 LFS families.
Characteristics of the study sample
Sample sociodemographic characteristics are presented in
Table 1. Twenty-seven individuals were carriers of a p53
mutation, of whom 10 had a cancer history. The remaining
18 individuals had a 50% risk of being a carrier of a p53
mutation. The majority of the participants was married or
living together and had children.
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Of the total sample, 32 individuals (71%) received advice
to undergo regular surveillance for LFS-related conditions.
Fifty percent (n = 9) of those at 50% risk and 85%
(n = 23) of the carriers received an advice for regular
surveillance (see Fig. 1). Ninety-one percent (n = 29)
received their advice for regular surveillance via the
clinical geneticist at the time of genetic counseling and
testing. Three at risk individuals received indirect advice
via the clinical geneticist (e.g., via their parents or brother/
sister who had undergone genetic counselling and testing
and were proven to be carriers).
Those who received advice to undergo regular surveil-
lance were signiﬁcantly more likely to be carriers (p = .01)
and to be older (mean age (sd) advice-versus no-advice-
Table 1 Demographics study
sample
Characteristics Total
(n = 45) N (%)
Compliers
(n = 25) N (%)
Non-compliers
(n = 7) N (%)
No advice
(N = 13) N (%)
Age (mean ± SD (range)) 40.6 ± 15.2 (17–75) 44.8 ± 14.4 39.7 ± 13.7 32.2 ± 15.1
Gender (female) 19 (42%) 10 (40%) 4 (57%) 5 (39%)
Marital status
Married/living together 31 (69%) 21 (84%) 6 (86%) 4 (31%)
Single 14 (31%) 4 (16%) 1 (14%) 9 (69%)
Education level
Low 14 (31%) 9 (36%) 2 (28%) 3 (23%)
Moderate 18 (40%) 9 (36%) 3 (43%) 6 (46%)
High 13 (29%) 7 (28%) 2 (29%) 4 (31%)
Children (yes) 25 (56%) 17 (68%) 3 (43%) 5 (39%)
Actual risk
Carrier 27 (60%) 20 (80%) 3 (43%) 4 (31%)
50% at risk 18 (40%) 5 (20%) 4 (57%) 9 (69%)
Cancer history (yes) 10 (22%) 9 (36%) 0 (0%) 1 (8%)
45 high risk LFS family members





















Fig. 1 Flowchart advice and
adherence to regular
surveillance for LFS
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123groep 43,7 (14,2) versus 30,2 (16,1); p = .01). No statis-
tically signiﬁcant differences were found between those
who did and did not receive an advice for regular sur-
veillance on the basis of gender, personal history of cancer
or hospital.
Type of surveillance advice
Respondents reported having received very diverse advice
on regular surveillance (Table 2). Of the total group, 78%
(n = 25) received advice for tailored screening, that is,
organ-targeted surveillance based on family cancer history
(e.g., colonoscopies at regular intervals if a relative has had
colorectal cancer). Additionally, 72% (n = 23) of the
respondents reported having received advice to undergo an
annual medical consultation, which includes an anamnesis
and/or physical examination.
Twelve of the fourteen female respondents were
25 years of age or older (7 carriers and 5 at 50% risk). Only
one of these women indicated that she had not been advised
to undergo regular breast cancer surveillance. This was
because she had undergone a bilateral mastectomy after
having being diagnosed with two primary breast tumors.
Five women were advised to undergo an annual mam-
mography, 4 to undergo an annual breast MRI, and 2
women were advised to undergo both. Thus, in total, 64%
(n = 7) of the female high risk family members aged 25 or
older who received an advice to undergo surveillance for
breast cancer were advised to undergo an annual mam-
mography. Two of the 14 women were younger than
25 years of age and therefore no advice for breast cancer
surveillance was given.
Adherence with the advice for regular surveillance
Of those who were advised to undergo regular surveillance
for LFS, 78% (n = 25) reported being fully compliant with
that advice (see Fig. 1). Seven respondents (3 carriers and
4 at risk) indicated that they had not been (fully) adherent;
they had not undergone (some of) the advised surveillance
methods and/or not as frequently as advised. All woman
who received advice about regular breast cancer surveil-
lance reported being compliant (n = 11). Additionally,
four individuals did not (fully) comply with the recom-
mended medical consultations, and four with the tailored
screening advice (colonoscopy (n = 2), ultrasound kidneys
(n = 1), examination by a dermatologist (n = 1), endo-
scopic ultrasound pancreas (n = 1), total blood count
(n = 2)). Carriers tended to be more likely to be (fully)
compliant with the advice for regular surveillance than
those at 50% risk (p = .08). No statistically signiﬁcant
differences were observed between compliers and non-
compliers on the basis of gender, age, personal history of
cancer or hospital.
Reasons for non-compliance
Of the seven individuals who reported not being (fully)
compliant with the screening advice, two indicated that
they did not believe that screening was particularly useful.
Two other individuals indicated they did not undergo
regular surveillance because they did not have any symp-
toms or complaints and therefore did not see any need for
surveillance. One individual indicated avoiding regular
surveillance because of fear of a tumor being detected, and
two others stated that regular surveillance was too time
consuming or difﬁcult to plan.
Possible psychological gains of surveillance
Perceived beneﬁts of and barriers to screening
The most prevalent perceived beneﬁts of regular surveil-
lance were early detection of cancer (90%), a feeling of
control (84%), and a sense of security (77%). The most
important perceived barriers to regular surveillance were
the possible negative effect on obtaining a mortgage, life
insurance and/or health insurance (42%), that it would
cause unnecessary worry (36%), and that it was impractical
or inconvenient (e.g. in relation to work, childcare, etc.)
(13%) (see Table 3).
Those who indicated that they had followed the advice
for regular surveillance were signiﬁcantly more likely to
Table 2 Screening recommendations received by high risk LFS
family members
Recommended screening Carriers 50% At risk Total
Males and females (n = 23) (n = 9) (n = 32)
Annual medical consultation* 18 (78%) 5 (56%) 23 (72%)
Tailored screening
a 19 (83%) 6 (67%) 25 (78%)
Females
b (n = 7) (n = 7) (n = 14)
Annual breast MRI
c 3 (43%) 3 (43%) 6 (43%)
Annual mammography
d 5 (71%) 2 (29%) 7 (50%)
* Medical consultation includes a anamnesis and/or physical exami-
nation by a physician
a Tailored screening refers to organ-targeted surveillance based on
family history, here including: colonoscopies (n = 9), endoscopic
ultrasound pancreas (n = 4), MRI pancreas (n = 4), examination by
a dermatologist (n = 14), ultrasound of kidneys (n = 10), urine
analysis (n = 5), total blood count (n = 5)
b Of the 14 women, 12 were aged C 25 years or older (7 carriers and
5 at 50% risk), 2 were aged\25 years (both at 50% risk)
c All women who were advised to undergo a regular breast MRI were
age 25 years or older
d All women who were advised to undergo a regular mammography
were age 25 years or older
Regular surveillance for Li-fraumeni syndrome 651
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(p = .02) and that it provided them with a feeling of
control (p = .04). Those who were adherent were also
more likely to indicate that regular surveillance reduces the
chance of cancer being detected in an advanced stage
(p = .09). Overall, those adherent with regular surveillance
reported signiﬁcantly more beneﬁts from surveillance than
those who were not (fully) adherent (p = .03). No signif-
icant differences were found between the adherent and
non-adherent groups with regard to the perceived barriers
of regular surveillance (see Table 3).
LFS-related distress and worries
No statistically signiﬁcant differences in psychological
distress (IES) or worry (CWS) were found between those
who received and adhered to advice for regular surveil-
lance, those who received advise to undergo surveillance
but did not do so (fully), and those who reported not having
received advice for regular surveillance. For the total
group, the mean score on the ‘intrusion’ subscale of the IES
was 5.1 (SD = 7.3) and on the CWS, 12.4 (SD = 3.2).
Nine individuals (20%) scored above the cutoff of 9 on the
IES, indicating clinically relevant levels of distress.
Discussion
To our knowledge, this study is the ﬁrst to investigate
which methods for regular surveillance, if any, are offered
to high risk LFS family members, the extent to which such
advice is followed, and the possible psychological burden
or beneﬁts associated with regular surveillance for health
conditions associated with LFS. Although the actual
medical beneﬁts of surveillance for LFS are limited, the
vast majority of LFS family members receive advice to
undergo regular surveillance and report being adherent
with the advice given.
Although the surveillance guidelines for LFS in the
Netherlands solely include regular breast surveillance from
age 20–25 years and an optional annual physical examina-
tion, this study shows that the speciﬁc screening advice
given to high risk LFS family members in the Netherlands is
more extensive and diverse than the guidelines. The large
majority receive tailored screening advice based on family
history. The national guidelines have recently been updated,
andintheseupdatedguidelinessurveillancebasedonfamily
history is included as optional [24]. This is in accordance
with the US guidelines for regular surveillance published by
the National Comprehensive Cancer Network [25].
Since regular surveillance for breast cancer is the only
surveillance method considered to be effective, it is
encouraging that all eligible high risk women aged 25 years
or older received advice to undergo regular breast cancer
surveillance, and adhere to this advice. It is notable that,
despite the controversy about possible increased radiation
sensitivity associated with p53 mutations [13, 26, 27],
approximately two-thirds of these women were advised to
undergo an annual mammography instead of a breast MRI.
In addition, the large majority of these high risk individuals
Table 3 Perceived beneﬁts &
barriers of screening for LFS
(n = 31)
* 1 case missing in analysis
a Signiﬁcant difference p B .05









(n = 6)* %
Beneﬁts of screening
Reduces the chance of cancer being detected




Reduces my fear of cancer 61% 72%
a 17%
a
Provides me with a feeling of control 84% 92%
a 50%
a
Gives me a sense of security 77% 84% 50%
Is a good way to detect cancer early 90% 92% 83%
Total scale score beneﬁts (mean ± SD) 20.6 ± 3.7 21.3 ± 3.4
a 17.7 ± 3.6
a
Barriers of screening
Can have a negative effect on my home mortgage
and/or life and health insurance
42% 44% 33%
Can cause unnecessary worry 36% 28% 67%
Causes inconvenience in my life 13% 8% 33%
Screening is not important, if I am diagnosed with
cancer it will be too late
3% 4% 0%
Is painful 0% 0% 0%
Is uncomfortable/embarrassing 10% 8% 17%
Total scale score barriers (mean ± SD) 12.8 ± 3.2 12.4 ± 2.8 14.0 ± 4.6
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123received tailored screening advice, based on their personal
family history of cancer.
As hypothesized, individuals who received advice for
regular surveillance and adhered to that advice reported
greater beneﬁts from regular surveillance, compared to
those who were not (fully) adherent. The main perceived
beneﬁt of regular surveillance was the possible early
detection of cancer. Additionally, regular surveillance pro-
videsasenseofcontrolandsecurity.Onlylimitedbarriersto
surveillance were reported, and no differences regarding
these barriers were found between those who were and were
not (fully) compliant. However, although not signiﬁcant,
those who were not (fully) compliant with the advice
received reported that regular surveillance may cause
unnecessary worry, is inconvenient or can cause practical
problems with ﬁnances or insurance.
Those who received and were compliant with advice for
regular surveillance did not report signiﬁcantly lower lev-
els of LFS-related distress and worries than the non/under-
compliers or those who reported not having being advised
to undergo regular surveillance. At the same time, regular
surveillance does not appear to result in any signiﬁcant
psychological burden for those who pursue it. Interestingly,
as reported earlier, levels of distress and worry among LFS
family members are, in general, relatively low and rather
comparable to the more common forms of hereditary
cancer [15].
Several limitations of this study should be noted. First,
although we attempted to capture the entire LFS population
in the Netherlands and the response rate was high (82%),
the sample size was relatively small. Larger international
studies are needed to conﬁrm our results. Second, the
cross-sectional nature of the study only allows us to speak
of statistical associations, rather than causal attributions.
Relatedly, due to the small numbers and high compliance
rate, it was not feasible to perform analyses to investigate
which sociodemographic, clinical and psychosocial vari-
ables were associated with non-compliance at the multi-
variate level. Finally, it should be noted that information on
advice received and compliance with that advice was based
on self-report.
In summary, this study is the ﬁrst to investigate the
advice for regular surveillance given to high risk LFS
family members, adherence with that advice, and perceived
beneﬁts of surveillance for LFS. Despite the fact that the
medical gains of regular surveillance are limited, the vast
majority of high risk family members are advised to
undergo surveillance and are adherent with that advice. LFS
family members have conﬁdence in the ability of regular
surveillance to detect cancer in an early stage, and thus this
gives them a sense of control and security. Offering regular
surveillance to high risk LFS family members may con-
tribute to their psychological well-being.
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